Novavax's XFG-adapted Nuvaxovid COVID vaccine approved in US, EU, Japan for 2026-2027 season

Novavax's partners received regulatory approvals for the XFG-adapted Nuvaxovid protein-based COVID-19 vaccine for the 2026-2027 vaccination season in the US, EU, and Japan. Novavax will continue earning royalties on net sales of the vaccine.

Detected & updated continuously · Source: Nebula